doi:

DOI: 10.3724/SP.J.1264.2011.00011

Chinese Journal of Multiple Organ Diseases in the Elderly (中华老年多器官疾病杂志) 2011/10:4 PP.329-332

Effect of tirofiban on short-term prognosis of elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention


Abstract:
Objective To evaluate the effect of tirofiban on short-term prognosis of elderly patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention(PCI). Methods Totally 325 ACS patients were divided into two groups: Tirofiban group (n = 210) and control group (n = 115). All subjects underwent PCI with drug-eluting stents. Patients in tirofiban group received tirofiban, in addition to aspirin and clopidogrel. Patients in control group received oral administration of aspirin and clopidogrel only. The general data, the rate of thrombolysis in myocardial infarction (TIMI) grade 3 flow immediately after PCI, the in-stent thrombosis incidence, mild and severe bleeding rate, platelet decrease rate, mortality, and incidences of myo-cardial infarction (MI) and target vessel revascularization(TVR) at 30 days after PCI were compared between the two groups. Results The rate of TIMI grade 3 flow immediately after PCI was significantly higher in Tirofiban group than in control group (99.05% vs 94.78%, P<0.05=. The in-stent thrombosis incidence was lower in Tirofiban group than in control group(0.47% vs 3.47%, P<0.01=. The mortality and incidences of MI and TVR at 30 days after PCI were lower in Tirofiban group than in control group(0.00% vs 2.61%, 0.47% vs 3.47%, and 0.47% vs 1.73%, P<0.01=. The mild bleeding rate was higher in Tirofiban group than in control group, with no significant difference (7.14% vs 4.35%, P>0.05).The rates of severe bleeding and platelets decrease were not significantly different between the two groups (0.00% vs 0.00%, and 0.95% vs 0.87%, P>0.05). Conclusion Tirofiban can improve the TIMI grade flow in elderly patients with ACS after PCI. It can also decrease the in-stent thrombosis incidence, mortality, and incidences of MI and TVR at 30 days after PCI, but do not increase the rates of severe bleeding and platelets decrease in these patients. So it can improve the short-term prognosis in elderly patients with ACS undergoing PCI.

Key words:elderly,acute coronary syndrome,percutaneous coronary intervention,Tirofiban,prognosis

ReleaseDate:2014-07-21 15:56:20



[1] The Restore Investigators. Effects of platelet glycoprotein Ⅱb/Ⅲa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis[J]. Circulation, 1997, 96(5): 1445-1453.

[2] Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS)Study Investigators. Inhibition of the platelet glycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable an-gina and non-Q-wave myocardial infarction[J]. N Engl J Med, 1998, 338(21): 1488-1497.

[3] 彭志松, 叶 飞, 陈绍良, 等. 血小板糖蛋白Ⅱb /Ⅲa受体拮抗剂治疗老年ACS的研究[J]. 实用老年医学, 2006, 20(5): 331-332.

[4] 陈 忠, 马根山, 冯 毅, 等. 国产替罗非班在高龄急性冠状动脉综合征患者介入治疗中的应用[J]. 中国介入心脏病学杂志, 2006, 14(6): 365-368.

[5] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 不稳定性心绞痛诊断和治疗建议[J]. 中华心血管病杂志, 2000, 28(5): 409-412.

[6] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会, 中国循环杂志编辑委员会. 急性心肌梗死诊断和治疗指南[J]. 中华心血管病杂志, 2001, 29(8): 710-725.

[7] The Platelet Receptor Inhibition In Ischemic Syndrome Management(PRISM)Study Investigators. A comparision of aspirin plus tirofiban with aspirin plus heparin for unstable angina[J]. N Engl J Med, 1998, 338(21): 1498-1505.

[8] Cutlip DE, Windecker S, Mehran R, et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions[J]. Circulation, 2007, 115(17): 2344-2351.

[9] Huynh T, Piazza N, DiBattiste PM, et al. Analysis of bleeding complications associated with glycoprotein Ⅱb/Ⅲa receptors blockade in patients with high risk acute coronary syndromes: insights from the PRISM-PLUS study[J]. Int J Cardiol, 2005, 100(1): 73-78.

PDF